• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
19
Oct
2018

Novartis’ $2B Takeover of Endocyte, Revolution-Warp Drive, & Amgen’s Foray in DNA Sequencing

/
Luke Timmerman
/
0
/
All
19 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Oct
2018

AbbVie Plunks Down $100M Upfront for Morphic’s Oral Integrin Inhibitors for Fibrosis

/
Luke Timmerman
/
3
/
All
18 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Oct
2018

Making it Easy to Share Biological Data: John Wilbanks on The Long Run Podcast

/
Luke Timmerman
/
0
/
All
17 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Oct
2018

Allogene’s Megabucks IPO, CVS-Aetna Muscling Through, & Consumer Genetics in the Mainstream

/
Luke Timmerman
/
0
/
All
12 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Oct
2018

The MIT Biotech Group Alumni: Where Are They Now?

/
Luke Timmerman
/
0
/
All, People
11 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Oct
2018

Nobel Highlights and Lowlights, MSK Fallout Continues, Pfizer CEO Stepping Down

/
Luke Timmerman
/
0
/
All
05 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Oct
2018

Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run

/
Luke Timmerman
/
0
/
All
03 Oct 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Sep
2018

Roche’s PD-L1 ‘Practice-Changer,’ J&J Dumps Geron, and Amarin’s Fish-Oil Surprise

/
Luke Timmerman
/
0
/
All
28 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Sep
2018

WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight

/
Luke Timmerman
/
0
/
All, Cancer
21 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Sep
2018

Health Data That Can Meet Pharma Standards: Amy Abernethy on The Long Run

/
Luke Timmerman
/
0
/
All
19 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Sep
2018

Baselga Brouhaha, a Shkreli Imitator, and Autoimmunity Strides from BMS and Gilead

/
Luke Timmerman
/
0
/
All
14 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Sep
2018

Telling Biotech Stories on TV: Listen to Meg Tirrell on The Long Run Podcast

/
Luke Timmerman
/
0
/
All
05 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Sep
2018

Fulcrum Gets $80M to Test Small Molecules Against Rare Disorders of Gene Expression

/
Luke Timmerman
/
3
/
All
05 Sep 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Aug
2018

Time and Money: What Are They Worth to a Young Scientist?

/
Boaz Vilozny
/
0
/
All
28 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Aug
2018

Exact Goes from Madison Wis. to Madison Ave. & IPO Candidates Get in Line

/
Luke Timmerman
/
0
/
All
24 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Aug
2018

Building Startups With Pharma Needs in Mind: Thong Le on The Long Run Podcast

/
Luke Timmerman
/
0
/
All
22 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Aug
2018

Alnylam Crosses the Threshold, Gilead’s Changing of the Guard & Gene Therapy Financings Galore

/
Luke Timmerman
/
0
/
All
17 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Aug
2018

The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast

/
Luke Timmerman
/
2
/
All
08 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Aug
2018

5AM, NEA Lead $50M Bet on Akouos, Crafting Gene Therapy for the Ear

/
Luke Timmerman
/
2
/
All
07 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Aug
2018

BeiGene’s Cash Haul, Illumina’s Big Q2, & Startups Keep Hiring Pharma Vets

/
Luke Timmerman
/
0
/
All
03 Aug 2018

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 54 55 56 57 58 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder